You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Carcinoma, Pancreatic Ductal

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Carcinoma, Pancreatic Ductal Trial in Trondheim (SonoVue, Chemotherapy)

Completed
  • Carcinoma, Pancreatic Ductal
  • Trondheim, Norway
    Department of Radiology, St Olavs Hospital
Jan 17, 2023

Selective Extended Dissection in Different Types of Pancreatic

Completed
  • Carcinoma, Pancreatic Ductal
  • Selective extended dissection of pancreaticoduodenectomy
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Feb 9, 2023

Predictive Factors for Resection and Survival in Type A

Not yet recruiting
  • Carcinoma, Pancreatic Ductal
  • Resection
  • No Resection
  • (no location specified)
Aug 3, 2022

Genes in Pancreatic Cancer for Better Treatment Selection

Active, not recruiting
  • Carcinoma, Pancreatic Ductal
  • Molecular Profiling
  • Kingston, Ontario, Canada
  • +3 more
Jan 25, 2023

Follow-up of High-risk Population of PDAC Based on EUS

Not yet recruiting
  • Carcinoma, Pancreatic Ductal
  • Endoscopic ultrasound
  • EUS-Fine needle aspiration
  • (no location specified)
Nov 18, 2022

PDAC - Pancreatic Ductal Adenocarcinoma, FAP Trial in New York ([68Ga]FAPI-46)

Recruiting
  • PDAC - Pancreatic Ductal Adenocarcinoma
  • FAP
  • New York, New York
    NYU Langone Health
May 3, 2022

PDAC Trial in Beijing (68Ga-FAPI Positron Emission Tomography-Computed Tomography)

Recruiting
  • PDAC
  • 68Ga-FAPI Positron Emission Tomography-Computed Tomography
  • Beijing, Beijing, China
    Peking Union Medical College Hospita
Mar 2, 2022

Carcinoma, Pancreatic Ductal, Prognosis Trial in Clichy, Lille, Saint-Cloud (Clinical value of 5 transcriptomic signatures to

Not yet recruiting
  • Carcinoma, Pancreatic Ductal
  • Prognosis
  • Clinical value of 5 transcriptomic signatures to personalize the therapeutic decision for L1 in PDAC
  • Biomarkers of tumor signatures (translational studies)
  • Clichy, France
  • +2 more
Jul 25, 2022

Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma Trial in New

Recruiting
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • +12 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Nov 30, 2022

Advanced Solid Tumor, Castration-Resistant Prostatic Cancer, Malignant Melanoma Trial in United States (MGC018, lorigerlimab)

Recruiting
  • Advanced Solid Tumor
  • +6 more
  • vobramitamab duocarmazine
  • lorigerlimab
  • Los Angeles, California
  • +7 more
Jan 10, 2023

Pancreatic Acinar Cell Carcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma Trial (Nab paclitaxel,

Not yet recruiting
  • Pancreatic Acinar Cell Carcinoma
  • +6 more
  • Nab paclitaxel
  • +5 more
  • (no location specified)
Oct 30, 2023

HER-2 Expression in Pancreatic Duct Adenocarcinoma

Completed
  • Pancreatic Adenocarcinoma
  • immunohistochemical approach
  • (no location specified)
Sep 20, 2023

Non-Small-Cell Lung Carcinoma, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma Trial (Liquid biopsy)

Not yet recruiting
  • Non-Small-Cell Lung Carcinoma
  • +2 more
  • Liquid biopsy
  • (no location specified)
Jan 24, 2023

Pancreatic Ductal Adenocarcinoma, Refractory NSCLC Trial in Washington (Daratumumab, KRAS vaccine, Nivolumab)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • Refractory Non-Small Cell Lung Cancer
  • Washington, District of Columbia
    Georgetown Lombardi Comprehensive Cancer Center
Sep 1, 2023

NSCLC, Colorectal Cancer, Pancreatic Ductal Carcinoma Trial in United States (JAB-3312)

Recruiting
  • Non-small Cell Lung Cancer
  • +6 more
  • Denver, Colorado
  • +3 more
Mar 13, 2022

Recurrence After Whipple's (RAW) Study

Active, not recruiting
  • Pancreatic Cancer
  • +13 more
  • Pancreaticoduodenectomy
  • Clayton, Victoria, Australia
  • +28 more
Jan 13, 2023

Unresectable Pancreatic Cancer, Unresectable Bile Duct Carcinoma, Unresectable Biliary Tract Carcinoma Trial (Tripegfilgrastim)

Not yet recruiting
  • Unresectable Pancreatic Cancer
  • +2 more
  • (no location specified)
Nov 13, 2023

NSCLC, Colorectal Cancer, Pancreatic Ductal Carcinoma Trial in Beijing, Henan (JAB-3312)

Recruiting
  • Non-small Cell Lung Cancer
  • +6 more
  • Beijing, Beijing, China
  • +4 more
Dec 28, 2021

Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers Trial (ABBV-400)

Not yet recruiting
  • Hepatocellular Carcinoma
  • +6 more
  • (no location specified)
Oct 10, 2023

Colorectal Tumors, NSCLC, Squamous Cell Carcinoma of the Head and Neck Trial (SGN-EGFRd2)

Not yet recruiting
  • Colorectal Neoplasms
  • +3 more
  • (no location specified)
Aug 1, 2023

Acinar Cell Carcinoma, Ampulla of Vater Adenocarcinoma, Cholangiocarcinoma Trial in Cleveland, Philadelphia (Pancreatectomy,

Recruiting
  • Acinar Cell Carcinoma
  • +7 more
  • Pancreatectomy
  • Lavage
  • Cleveland, Ohio
  • +1 more
Sep 7, 2022

Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation, BRCA2 Mutation Trial in Boston, New York (Melphalan, BCNU, Vitamin B12B)

Recruiting
  • Pancreatic Adenocarcinoma Metastatic
  • +14 more
  • Boston, Massachusetts
  • +1 more
Dec 6, 2022

Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8 Trial

Not yet recruiting
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • +3 more
  • Biopsy
  • +8 more
  • (no location specified)
Jan 13, 2023

Colorectal Tumors, NSCLC, Stomach Tumors Trial (SGN-CEACAM5C)

Not yet recruiting
  • Colorectal Neoplasms
  • +5 more
  • (no location specified)
Nov 9, 2023

Minimal Residual Disease, KRAS G12D, KRAS G12R Trial in United States (ELI-002 2P)

Recruiting
  • Minimal Residual Disease
  • +11 more
  • ELI-002 2P
  • Duarte, California
  • +10 more
Jan 18, 2023